N-[(1S)-2-hydroxy-1-phenylethyl]-3-pyridin-4-yl-1H-pyrazole-5-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(1S)-2-hydroxy-1-phenylethyl]-3-pyridin-4-yl-1H-pyrazole-5-carboxamide
• 化学式: C₁₇H₁₆N₄O₂
• 分子量: 308.33
• InChiKey: JVZYTMZXIGIASV-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  90.9
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE KINASES
  申请人：TRANSLATIONAL DRUG DEV LLC

  公开号：WO2018094362A1

  公开（公告）日：2018-05-24

  The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.

  本发明涉及某些酰胺和杂环化合物。本发明还涉及利用这些化合物治疗多种疾病，包括自身免疫性疾病、心血管疾病、炎症、中枢神经系统疾病、动脉血栓性疾病、纤维化疾病、青光眼和肿瘤性疾病。
• Heterocyclic compounds as kinase inhibitors
  申请人：TRANSLATIONAL DRUG DEVELOPMENT, LLC

  公开号：US10807966B2

  公开（公告）日：2020-10-20

  The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.

  本发明涉及某些酰胺和杂环化合物。本发明还涉及使用这些化合物治疗多种疾病，包括自身免疫性疾病、心血管疾病、炎症、中枢神经系统疾病、动脉血栓性疾病、纤维化疾病、青光眼和肿瘤性疾病。
• HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
  申请人：TRANSLATIONAL DRUG DEVELOPMENT, LLC

  公开号：US20190284157A1

  公开（公告）日：2019-09-19

  The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.